BioCryst Pharmaceuticals, Inc. (BCRX)

5,26 -0,01 (-0,19%) Alla chiusura: 04:00PM EDT

BioCryst Pharmaceuticals, Inc.

4505 Emperor Boulevard
Suite 200
Durham, NC 27703
United States
919 859 1302
https://www.biocryst.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 536

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jon P. Stonehouse	CEO, President & Executive Director	1,23M	647,14k	1961
Mr. Anthony J. Doyle	Senior VP, CFO & Interim Principal Accounting Officer	845,93k	N/D	1980
Ms. Alane P. Barnes	Senior VP, Chief Legal Officer & Corporate Secretary	794,75k	N/D	1966
Dr. Helen M. Thackray FAAP, M.D.	Chief Research & Development Officer	976,15k	N/D	1968
Mr. Charles K. Gayer	Senior VP & Chief Commercial Officer	794,12k	N/D	1971
Mr. John D. Bluth	Chief Communications Officer	N/D	N/D	1973
Ms. Stephanie Angelini	Chief People Officer	N/D	N/D	N/D
Dr. William P. Sheridan MBBS	Chief Development Officer	784,09k	4,4M	1955
Dr. Yarlagadda S. Babu Ph.D.	Chief Discovery Officer	691,45k	1,25M	1953
Ms. Jinky Ang Rosselli	Chief Data & Insights Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Governance aziendale

L'ISS Governance QualityScore di BioCryst Pharmaceuticals, Inc. al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 3; diritti degli azionisti: 8; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.